Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Zacks Investment Research

11 Jun 2026, 22:51 UTC · 1h ago

Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims

4 claims · each scored for market impact

What matters in this story

1
Adma Biologics currently holds a Zacks Rank #5 (Strong Sell). — A 'Strong Sell' rating from a quantitative ranking system is a direct bearish signal for the stock's near-term price action.
-0.60
2
Zacks Consensus Estimates project Adma Biologics' full-year earnings to grow by 40% to $0.84 per share. — Significant projected earnings growth is fundamentally positive, though tempered by the current bearish rank.
+0.40
3
Adma Biologics' Forward P/E ratio of 10.1 is a significant discount compared to its industry average of 20.9. — A lower-than-average valuation suggests the stock may be undervalued relative to peers.
+0.20
4
The Medical - Biomedical and Genetics industry is ranked in the bottom 38% of all industries tracked by Zacks. — Weak industry-wide ranking indicates systemic headwinds for companies in this specific sector.